Revance Therapeutics Inc (NASDAQ:RVNC)
| 7.05 Delayed Data As of Nov 28 |  +0.16 / +2.32%Today’s Change | 5.72 Today|||52-Week Range 37.98 | -61.81% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Quarter Trend | |||||
|---|---|---|---|---|---|---|
| Quarter 3 2018 | Quarter 4 2018 | Quarter 1 2019 | Quarter 2 2019 | |||
| Operating Activities | Net Income / Starting Line | -32.8M | -40.6M | -35.3M | -37.4M | |
| Depreciation | 444.0K | 475.0K | 628.0K | 790.0K | ||
| Total Other Cash Flow | 2.4M | 3.7M | 3.6M | 3.8M | ||
| Funds From Operations | -30.0M | -36.5M | -31.1M | -32.8M | ||
| Funds From/For Other Operating Expenses | -4.6M | -5.3M | -19.7M | -3.5M | ||
| Net Cash Flow - Operating Activities | -25.4M | -31.1M | -11.4M | -29.3M | ||
| Investing | Increase In Investments | 0.00 | -102.7M | -127.4M | -37.6M | |
| Decrease In Investments | 32.0M | 163.4M | 25.0M | 92.0M | ||
| Capital Expenditures | -3.0M | -1.6M | -1.1M | -375.0K | ||
| Fixed Asset Disposal | 1.4M | 4.0K | 7.0K | 0.00 | ||
| Net Assets From Acquisitions | 0.00 | -100.0K | 0.00 | 0.00 | ||
| Other Investing - Uses | 0.00 | 100.0K | 0.00 | 0.00 | ||
| Net Cash Flow Investing | 30.4M | 59.1M | -103.4M | 54.0M | ||
| Financing | Short Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Long Term Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Long Term Debt Reduction | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Net Proceeds Stock Sale | -918.0K | 2.4M | 106.9M | 43.0K | ||
| Common Preferred Redeemed | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Common Dividends | -- | -- | -- | -- | -- | |
| Cash Dividends Paid - Total | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Other Sources - Financing | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Other Uses - Financing | -1.8M | 2.2M | 0.00 | 0.00 | ||
| Net Cash Flow - Financing | 895.0K | 164.0K | 106.9M | 43.0K | ||
| Exchange Rate | Effect of Exchange Rate on Cash | -- | -- | -- | -- | -- |
| Net Change In Cash | 5.9M | 28.1M | -8.0M | 24.8M | ||
